Rhona Eveleigh1, Janneke Grutters2, Esther Muskens3, Richard Oude Voshaar4, Chris van Weel5, Anne Speckens6, Peter Lucassen3. 1. Department of Primary and Community Care, rhona.eveleigh@radboudumc.nl. 2. Department for Health Evidence and Department of Operating Rooms, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 3. Department of Primary and Community Care. 4. University Center for Psychiatry & Interdisciplinary Center for Psychopathology of Emotion regulation (ICPE), University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Primary and Community Care, Australian Primary Health Care Research Institute, Australian National University, Canberra, Australia, and. 6. Department of Psychiatry, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Antidepressant prescriptions have increased exponentially, burdening health care costs. OBJECTIVE: To evaluate the costs and effects of an antidepressant cessation advice in case of inappropriate long-term use in primary care, i.e. long-term usage without a (current) indication. METHODS: A economic evaluation during 1-year follow-up was performed, from a societal perspective, as part of a cluster-randomised controlled clinical trial (PANDA). Costs were assessed using the Trimbos/iMTA questionnaire for costs associated with psychiatric illness. Health-related quality of life was measured using the EuroQol 5D. Outcome was costs per quality adjusted life year (QALY). Missing values were estimated using multiple imputation, bootstrap simulations were performed to address the uncertainty surrounding the incremental cost-effectiveness ratios (ICERs). RESULTS: There was no difference in average QALYs between the intervention (0.70) and control group (0.72) [difference -0.02 (95% CI -0.05 to 0.10)]. The intervention group, however, was less expensive than the control group (total costs €3636 versus €5267, respectively). Most cost-effectiveness pairs were located in the south-west quadrant of the cost-effectiveness plane, implying the intervention was less effective but also less costly. The ICER of the pooled data was €70,180, meaning that for one QALY lost, €70,180 is saved. CONCLUSIONS: This study shows that an antidepressant cessation advice given to patients (and their FPs) with inappropriate long-term antidepressant usage, albeit not effective, does seem to result in a reduction of societal costs. This reduction in costs is mostly due to reduction of productivity losses, possibly due to patient empowerment and loss of stigma.
RCT Entities:
BACKGROUND: Antidepressant prescriptions have increased exponentially, burdening health care costs. OBJECTIVE: To evaluate the costs and effects of an antidepressant cessation advice in case of inappropriate long-term use in primary care, i.e. long-term usage without a (current) indication. METHODS: A economic evaluation during 1-year follow-up was performed, from a societal perspective, as part of a cluster-randomised controlled clinical trial (PANDA). Costs were assessed using the Trimbos/iMTA questionnaire for costs associated with psychiatric illness. Health-related quality of life was measured using the EuroQol 5D. Outcome was costs per quality adjusted life year (QALY). Missing values were estimated using multiple imputation, bootstrap simulations were performed to address the uncertainty surrounding the incremental cost-effectiveness ratios (ICERs). RESULTS: There was no difference in average QALYs between the intervention (0.70) and control group (0.72) [difference -0.02 (95% CI -0.05 to 0.10)]. The intervention group, however, was less expensive than the control group (total costs €3636 versus €5267, respectively). Most cost-effectiveness pairs were located in the south-west quadrant of the cost-effectiveness plane, implying the intervention was less effective but also less costly. The ICER of the pooled data was €70,180, meaning that for one QALY lost, €70,180 is saved. CONCLUSIONS: This study shows that an antidepressant cessation advice given to patients (and their FPs) with inappropriate long-term antidepressant usage, albeit not effective, does seem to result in a reduction of societal costs. This reduction in costs is mostly due to reduction of productivity losses, possibly due to patient empowerment and loss of stigma.
Authors: Emma Maund; Beth Stuart; Michael Moore; Christopher Dowrick; Adam W A Geraghty; Sarah Dawson; Tony Kendrick Journal: Ann Fam Med Date: 2019-01 Impact factor: 5.166
Authors: Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens Journal: Cochrane Database Syst Rev Date: 2021-04-15
Authors: Tony Kendrick; Adam W A Geraghty; Hannah Bowers; Beth Stuart; Geraldine Leydon; Carl May; Guiqing Yao; Wendy O'Brien; Marta Glowacka; Simone Holley; Samantha Williams; Shihua Zhu; Rachel Dewar-Haggart; Bryan Palmer; Margaret Bell; Sue Collinson; Imogen Fry; Glyn Lewis; Gareth Griffiths; Simon Gilbody; Joanna Moncrieff; Michael Moore; Una Macleod; Paul Little; Christopher Dowrick Journal: Trials Date: 2020-05-24 Impact factor: 2.279
Authors: Hannah M Bowers; Samantha J Williams; Adam W A Geraghty; Emma Maund; Wendy O'brien; Geraldine Leydon; Carl R May; Tony Kendrick Journal: BMJ Open Date: 2019-07-04 Impact factor: 2.692
Authors: Hannah M Bowers; Tony Kendrick; Marta Glowacka; Samantha Williams; Geraldine Leydon; Carl May; Chris Dowrick; Joanna Moncrieff; Rebecca Laine; Yvonne Nestoriuc; Gerhard Andersson; Adam W A Geraghty Journal: BMJ Open Date: 2020-03-08 Impact factor: 2.692